# Prenosis

> Prenosis is a Chicago biotech that built the first AI diagnostic the FDA ever authorized to help diagnose and predict sepsis. Its Sepsis ImmunoScore reads 22 signals from a patient's blood and vitals, then hands clinicians a risk score and category instead of one more alert to ignore. The tool sits on a decade-old biobank of 138,000+ specimens and now ships to U.S. hospitals through Roche.

- **Founded:** 2014
- **Headquarters:** Chicago, United States
- **Founders:** Bobby Reddy Jr. (Co-Founder & CEO), Rashid Bashir (Academic Co-Founder & Advisor)
- **Team size:** ~44 employees
- **Products:** Sepsis ImmunoScore, Immunix, Prenosis Biobank
- **Notable:** First and only AI diagnostic tool authorized by the FDA (De Novo) for sepsis, April 3, 2024, Sepsis ImmunoScore named to TIME's 200 Best Inventions of 2024, Bobby Reddy Jr. named to Crain's Chicago 40 Under 40 (2024)

## Products & services

- **Sepsis ImmunoScore** — The first FDA De Novo-authorized AI/ML Software as a Medical Device for sepsis. It combines 22 parameters - biomarkers such as procalcitonin and C-reactive protein plus lab values and vital signs - into a risk score and four risk categories that predict sepsis, ICU admission, mechanical ventilation, and mortality within 24 hours. Integrates into hospital EHRs and shows how each parameter contributed to the score.
- **Immunix** — Prenosis' proprietary precision medicine platform, built on the company's biobank, used to develop and deploy biology-driven clinical tools in real-time hospital workflows. Immunix enabled the creation and deployment of the Sepsis ImmunoScore.
- **Prenosis Biobank** — A biobank described as the world's largest biomarker-plus-clinical-data resource for acute care patients with suspected serious infection - 138,000+ longitudinal specimens from 35,000+ patients, built over a decade with 10+ partner hospitals and housed in a Biosafety Level 2 lab in Chicago.

## Achievements

- First and only AI diagnostic tool authorized by the FDA (De Novo) for sepsis, April 3, 2024
- Sepsis ImmunoScore named to TIME's 200 Best Inventions of 2024
- Bobby Reddy Jr. named to Crain's Chicago 40 Under 40 (2024)
- Bobby Reddy Jr. named to the TIME100 Health list (2025)
- Validation study published in NEJM AI with diagnostic AUC up to 0.85
- Built a biobank of 138,000+ specimens from 35,000+ patients

## Latest updates

- **2026-01** — Closed a $20M Series A led by PACE Healthcare Capital and a $20M BARDA contract, with plans to expand into pneumonia, acute heart failure, ARDS and acute kidney injury.
- **2025-05** — Bobby Reddy Jr. named to the TIME100 Health list of influential people in health.
- **2024-12** — Validation study published in NEJM AI confirms the Sepsis ImmunoScore's diagnostic and predictive power.
- **2024-10** — Sepsis ImmunoScore named one of TIME's 200 Best Inventions of 2024.
- **2024-04** — FDA grants De Novo authorization for the Sepsis ImmunoScore; Roche announces exclusive 5-year U.S. distribution.

## Links

- Website: https://prenosis.com
- LinkedIn: https://www.linkedin.com/company/prenosis
- Twitter/X: https://twitter.com/PrenosisInc
- YouTube: https://www.youtube.com/@prenosis1311
- Instagram: https://www.instagram.com/prenosis/

---

Profile page: https://yespress.io/prenosis
Published by YesPress — https://yespress.io
Last updated: 2026-08-20